Neurodegenerative disease pathways are perturbed in patients with cancer who self-report cognitive changes and anxiety: A pathway impact analysis.

Autor: Oppegaard KR; Department of Physiological Nursing, University of California San Francisco, San Francisco, California, USA.; The Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, University of Massachusetts Boston, Boston, Massachusetts, USA., Mayo SJ; Princess Margaret Cancer Centre, University Health Network, Lawrence S. Bloomberg School of Nursing, University of Toronto, Toronto, Ontario, Canada., Armstrong TS; Neuro-Oncology Branch, Office of Patient-Centered Outcomes Research, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Dokiparthi V; Pennsylvania State University, University Park, Pennsylvania, USA., Melisko M; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Levine JD; School of Dentistry, University of California San Francisco, San Francisco, California, USA., Olshen AB; Department of Epidemiology and Biostatistics, Bakar Computational Health Sciences Institute, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Anguera JA; Weill Institute for Neurosciences, Kavli Institute for Fundamental Neuroscience, Sandler Neurosciences Center, University of California San Francisco, San Francisco, California, USA., Roy R; Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California San Francisco, San Francisco, California, USA., Paul S; Department of Physiological Nursing, University of California San Francisco, San Francisco, California, USA., Cooper B; Department of Physiological Nursing, University of California San Francisco, San Francisco, California, USA., Conley YP; School of Nursing, University of Pittsburg, Pittsburgh, Pennsylvania, USA., Hammer MJ; The Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Miaskowski C; Departments of Physiological Nursing and Anesthesia and Perioperative Care, Pain and Addiction Research Center, University of California San Francisco, San Francisco, California, USA., Kober KM; Department of Physiological Nursing, Bakar Computational Health Sciences Institute, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.

Publikováno v: Cancer [Cancer] 2024 Aug 15; Vol. 130 (16), pp. 2834-2847. Date of Electronic Publication: 2024 Apr 27.

Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.

Autor: Northrop A; Department of Surgery, University of California San Francisco, San Francisco, CA 94158, United States., Christofferson A; Department of Surgery, University of California San Francisco, San Francisco, CA 94158, United States., Umashankar S; Department of Surgery, University of California San Francisco, San Francisco, CA 94158, United States., Melisko M; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA 94158, United States., Castillo P; Department of Surgery, University of California San Francisco, San Francisco, CA 94158, United States., Brown T; Patient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States., Heditsian D; Patient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States., Brain S; Patient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States., Simmons C; Patient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States., Hieken T; Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN 55905, United States., Ruddy KJ; Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States., Mainor C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, United States., Afghahi A; Department of Medicine, University of Colorado, Aurora, CO 80045, United States., Tevis S; Department of Surgery, University of Colorado, Aurora, CO 80045, United States., Blaes A; Department of Medicine, Division of Hematology/Oncology, University of Minnesota, Minneapolis, MN 55455, United States., Kang I; Department of Medical Oncology & Therapeutics Research, City of Hope Orange County, Irvine, CA 92618, United States.; Department of Medicine, University of Southern California, Los Angeles, CA 90089, United States., Asare A; Department of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.; Quantum Leap Healthcare Collaborative, San Francisco, CA 94158, United States., Esserman L; Department of Surgery, University of California San Francisco, San Francisco, CA 94158, United States., Hershman DL; Division of Hematology/Oncology, Department of Medicine, Columbia University, New York, NY 10032, United States., Basu A; Department of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.

Publikováno v: Journal of the American Medical Informatics Association : JAMIA [J Am Med Inform Assoc] 2024 Aug 19. Date of Electronic Publication: 2024 Aug 19.

Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.

Autor: Umashankar S; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Li M; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Blevins K; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Kim MO; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Majure M; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Park J; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Huppert LA; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Melisko M; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Rugo HS; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Esserman L; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA., Chien AJ; Helen Diller Family Cancer Center, University of California San Francisco, San Franciso, CA, USA. jo.chien@ucsf.edu.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Apr; Vol. 204 (3), pp. 509-520. Date of Electronic Publication: 2024 Jan 09.

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Autor: Albain KS; Loyola University Chicago Stritch School of Medicine, Maywood, Illinois., Yau C; University of California San Francisco, San Francisco, California., Petricoin EF; George Mason University, Fairfax, Virginia., Wolf DM; University of California San Francisco, San Francisco, California., Lang JE; Cleveland Clinic, Cleveland, Ohio., Chien AJ; University of California San Francisco, San Francisco, California., Haddad T; Mayo Clinic Rochester, Rochester, Minnesota., Forero-Torres A; University of Alabama at Birmingham, Birmingham, Alabama., Wallace AM; University of California San Diego, La Jolla, California., Kaplan H; Swedish Cancer Institute, Seattle, Washington., Pusztai L; Yale University, New Haven, Connecticut., Euhus D; Johns Hopkins University, Baltimore, Maryland., Nanda R; University of Chicago, Chicago, Illinois., Elias AD; University of Colorado Denver, Aurora, Colorado., Clark AS; University of Pennsylvania, Philadelphia, Pennsylvania., Godellas C; Loyola University Chicago Stritch School of Medicine, Maywood, Illinois., Boughey JC; Mayo Clinic Rochester, Rochester, Minnesota., Isaacs C; Georgetown University, Washington, District of Columbia., Tripathy D; University of Texas MD Anderson Cancer Center, Houston, Texas., Lu J; University of Southern California, Los Angeles, California., Yung RL; University of Washington, Seattle, Washington., Gallagher RI; George Mason University, Fairfax, Virginia., Wulfkuhle JD; George Mason University, Fairfax, Virginia., Brown-Swigart L; University of California San Francisco, San Francisco, California., Krings G; University of California San Francisco, San Francisco, California., Chen YY; University of California San Francisco, San Francisco, California., Potter DA; University of Minnesota, Minneapolis, Minnesota., Stringer-Reasor E; University of Alabama at Birmingham, Birmingham, Alabama., Blair S; University of California San Diego, La Jolla, California., Asare SM; Quantum Leap Healthcare Collaborative, San Francisco, California., Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, California., Hirst GL; University of California San Francisco, San Francisco, California., Singhrao R; University of California San Francisco, San Francisco, California., Buxton M; University of California San Francisco, San Francisco, California., Clennell JL; University of California San Francisco, San Francisco, California., Sanil A; Berry Consultants, LLC, Houston, Texas., Berry S; Berry Consultants, LLC, Houston, Texas., Asare AL; Quantum Leap Healthcare Collaborative, San Francisco, California., Matthews JB; University of California San Francisco, San Francisco, California., DeMichele AM; University of Pennsylvania, Philadelphia, Pennsylvania., Hylton NM; University of California San Francisco, San Francisco, California., Melisko M; University of California San Francisco, San Francisco, California., Perlmutter J; Gemini Group, Ann Arbor, Michigan., Rugo HS; University of California San Francisco, San Francisco, California., Symmans WF; University of Texas MD Anderson Cancer Center, Houston, Texas., Van't Veer LJ; University of California San Francisco, San Francisco, California., Yee D; University of Minnesota, Minneapolis, Minnesota., Berry DA; Berry Consultants, LLC, Houston, Texas., Esserman LJ; University of California San Francisco, San Francisco, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 16; Vol. 30 (4), pp. 729-740.

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.

Autor: Record H; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Clelland E; School of Medicine, University of California San Francisco, San Francisco, CA, USA., Rothschild HT; School of Medicine, University of California San Francisco, San Francisco, CA, USA., Kaur M; School of Medicine, University of California San Francisco, San Francisco, CA, USA., Chien AJ; Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Melisko M; Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Rugo HS; Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Mujir F; Department of Surgery, Division of Surgical Oncology, University of California San Francisco, San Francisco, CA, USA., Huppert L; Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Mukhtar RA; Department of Surgery, Division of Surgical Oncology, University of California San Francisco, San Francisco, CA, USA. Rita.mukhtar@ucsf.edu.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2023 Oct 26; Vol. 9 (1), pp. 88. Date of Electronic Publication: 2023 Oct 26.